Treatment of central nervous system inflammatory demyelinating disorders: bedside to the bench by Chan, KH
Title Treatment of central nervous system inflammatorydemyelinating disorders: bedside to the bench
Author(s) Chan, KH
Citation
The 25th Annual Scientific Meeting of the Hong Kong
Neurological Society, Hong Kong, 3-4 November 2012. In Hong





Hong Kong Medical Journal. Copyright © Hong Kong Academy
of Medicine Press.; This work is licensed under a Creative
Commons Attribution-NonCommercial-NoDerivatives 4.0
International License.
26      Hong Kong Med J Vol 18 No 6 # Supplement 5 # December 2012
Current Advances in Biomarkers in Multiple Sclerosis
Thomas Berger




















(4)	 monitoring	disease-modifying	 therapies:	neutralising	antibodies	 (against	 interferon	beta	and	
natalizumab),	risk	assessment	and	treatment	stratification	(anti-JC	virus	antibody	assays)
Treatment of Central Nervous System Inflammatory Demyelinating Disorders: 
Bedside to the Bench
KH Chan
Department of Medicine, The University of Hong Kong, Hong Kong SAR
Central	nervous	system	inflammatory	demyelinating	disorders	(CNS	IDD)	are	important	diseases	affecting	
patients	of	a	wide	age	range,	and	are	potentially	treatable.	CNS	IDD	can	result	 in	major	neurological	
disabilities	and	even	mortality.	Both	classical	multiple	sclerosis	 (CMS)	and	neuromyelitis	optica	are	
predominantly	characterised	by	relapsing	attacks	of	CNS	inflammatory	demyelination.	The	diagnosis	of	
which	may	be	difficult	especially	in	the	early	phase.	Excitement	has	arisen	from	increasing	numbers	of	
disease-modifying	drugs	(DMDs)	available	for	CMS	in	recent	years.	Beta-interferon	and	glatiramer	acetate	
are	certainly	first-line	DMDs.	Natalizumab,	fingolimod	and	mitoxantrone	are	approved	second-line	DMDs	
for	relapsing	multiple	sclerosis	patients.	Other	DMDs	that	may	be	used	in	refractory	patients	include	
alemtuzumab,	teriflunomide	and	rituximab.	However,	availability,	costs	and	rare	but	serious	side-effects	
are	practical	issues	that	may	limit	the	choice	of	treatment	for	these	patients.	How	about	novel	therapies?
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